Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HeartBeam ( (BEAT) ) has issued an update.
On July 11, 2025, HeartBeam, Inc. held its annual meeting of stockholders virtually, where a quorum was established with 55.32% of outstanding votes represented. During the meeting, nine directors were elected for a one-year term, the appointment of CBIZ CPAs P.C. as the independent accounting firm was ratified, and an amendment to increase authorized shares in the 2022 Equity Incentive Plan was proposed.
The most recent analyst rating on (BEAT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on HeartBeam stock, see the BEAT Stock Forecast page.
Spark’s Take on BEAT Stock
According to Spark, TipRanks’ AI Analyst, BEAT is a Underperform.
HeartBeam’s overall score reflects its challenging financial position with significant net losses and cash flow issues. Despite promising developments in FDA clearances and market opportunities that could drive future growth, the current financial instability and bearish technical indicators weigh heavily on the stock’s attractiveness. The earnings call provides some optimism about future potential, but the immediate financial concerns dominate the overall assessment.
To see Spark’s full report on BEAT stock, click here.
More about HeartBeam
HeartBeam, Inc. operates in the healthcare technology industry, focusing on developing innovative cardiac care solutions.
Average Trading Volume: 101,682
Technical Sentiment Signal: Sell
Current Market Cap: $42.26M
For an in-depth examination of BEAT stock, go to TipRanks’ Overview page.